# Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

> **NCT02689284** · PHASE1,PHASE2 · COMPLETED · sponsor: **MacroGenics** · enrollment: 95 (actual)

## Conditions studied

- Gastric Cancer
- Stomach Cancer
- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** Margetuximab 10 mg/kg
- **BIOLOGICAL:** Margetuximab 15 mg
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02689284
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2021-01
- **Final completion:** 2021-01
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689284, "Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02689284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*